YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Coloplast A/S Major shareholder announcement Reference is made to the press release issued by Coloplast A/S on 4 September 2026 regarding the expected implementation of the generational change in the ultimate ownership of Coloplast A/S. Co…
Company Logo The global ostomy dressings market is projected to grow from USD 3.80 billion in 2026 to USD 4.73 billion by 2031, at a 4.4% CAGR. Growth is driven by rising colorectal cancer and inflammatory bowel disease cases, aging popula…
Coloplast A/S Please see enclosed pdf. For more information and calendar invitations for upcoming events, please visit: https://investor.coloplast.com/investor-relations/financial-calendar-and-events/ Kind regards, Investor Relations Colop…
Coloplast A/S Coloplast has been informed that the Danish Financial Supervisory Authority (FSA) has today announced that it has notified Niels Peter Louis-Hansen that it has granted an exemption from the obligation to make a mandatory take…
* Coloplast A/S press release [https://www.coloplast.com/contentassets/9bed9a86070d456e91c4552e7a479f16/07_2026_9m_2025_26_earnings_release.pdf] (CLPBF [https://seekingalpha.com/symbol/CLPBF]): Q3 Non-GAAP EPS of DKK 6.55. * Revenue of DKK…
This article first appeared on GuruFocus. Organic Revenue Growth: 6% in Q3 and for the first nine months. Reported Revenue: Increased by DKK568 million (around 3%) for the first nine months. EBIT Growth (Constant Currencies): 5% in Q3 and…
Rupal Bhansali, CEO of Double Duty Money Management, finds bargains in France, Denmark, and Brazil. Why she likes UPS. Continue Reading
Fundsmith Equity Fund was down by 2.9% in the first 6 months of the year, 14.1 percentage points less than what is perhaps the most obvious comparator, the MSCI World Index. The fund, in its semi-annual fund letter, stated that it began ac…
Coloplast A/S Titan PrimeTitan Prime, an inflatable penile prosthesis (IPP), will be available in the U.S. in late 2026. ·GlobeNewswire Inc. The global leader within intimate healthcare today announced FDA approval of Titan Prime, an infla…
The European stock market has experienced a mixed performance recently, with the pan-European STOXX Europe 600 Index showing modest gains amid easing geopolitical tensions and strong corporate earnings. However, concerns over potential U.S…
As the pan-European STOXX Europe 600 Index concluded a turbulent week with modest gains, investor sentiment was buoyed by easing geopolitical tensions and robust corporate earnings across the region. However, concerns over potential U.S. t…
This article first appeared on GuruFocus. Ostomy Care Organic Growth: 5% for the first six months; 7% in Q2. Continence Care Organic Growth: 7% for the first six months; 8% in Q2. Voice & Respiratory Care Organic Growth: 8% for the first s…
2025/26 Interim financial results, H1 2025/26 1 October 2025 - 31 March 2026 Coloplast delivered Q2 organic growth of 6% and 6% EBIT growth1 in constant currencies. Strong quarter in Chronic Care and Interventional Urology, challenging qua…
In recent weeks, the European market has experienced modest gains amid easing geopolitical tensions and strong corporate earnings, although concerns over potential U.S. tariffs on EU goods have weighed on investor sentiment. As the Europea…
The European stock market recently experienced a volatile week, with modest gains in the pan-European STOXX Europe 600 Index, as investor sentiment was buoyed by easing geopolitical tensions and strong corporate earnings. However, looming…
As European markets navigate a landscape marked by stalled geopolitical negotiations and fluctuating oil prices, the pan-European STOXX Europe 600 Index remains relatively stable, with corporate earnings showing positive momentum. Amid the…
As the European market navigates through a landscape marked by stable interest rates and geopolitical uncertainties, the pan-European STOXX Europe 600 Index has managed to maintain a steady course, reflecting cautious optimism amid positiv…
As the pan-European STOXX Europe 600 Index ended the week broadly flat amid stalled geopolitical negotiations and fluctuating oil prices, investors are keenly observing potential opportunities in undervalued stocks. In this context, identi…
Coloplast A/S The contract is awarded for products that bring improvement to the healthcare industry. Coloplast, a global medical device company and market leader in intimate healthcare, has received an Innovative Technology contract for B…
Coloplast A/S Announcement no. 04/2026 Inside information Coloplast revises the financial guidance on organic growth and EBIT growth in constant currencies before special items for FY 2025/26, reflecting a slower market recovery in the ski…
Coloplast A/S Tuesday, 12 May 2026 at 11:00 - 12:00 CEST In connection with the publication of Coloplast’s interim financial results for H1 2025/26, to be released same day around 07:30 CEST, Coloplast will host a conference call to presen…
Coloplast A/S Please see enclosed pdf. Update to Financial Calendar Dates Coloplast has updated the dates in its financial calendar for the publication of the FY Financial Statements 2025/26 and the Annual General Meeting 2026. The updated…
* Coloplast A/S press release [https://static.seekingalpha.com/uploads/sa_presentations/406/121406/original.pdf] (CLPBF [https://seekingalpha.com/symbol/CLPBF]): Q1 * Revenue of DKK7.04B (+0.1% Y/Y). MORE ON COLOPLAST A/S * Coloplast A/S (…
This article first appeared on GuruFocus. Organic Revenue Growth: 6% in Q1 2025/26. EBIT Growth: 3% in constant currencies before special items. Return on Invested Capital: 15% after tax and before special items. Interventional Urology Org…
2025/26 Interim financial results, Q1 2025/26 1 October 2025 - 31 December 2025 Coloplast delivered Q1 organic growth of 6% and EBIT growth1 in constant currencies of 3%. Reported revenue in DKK grew 0%, reflecting 4%-points negative impac…
As the European markets navigate a landscape marked by earnings optimism amidst trade and geopolitical concerns, the pan-European STOXX Europe 600 Index has shown resilience with modest gains. Against this backdrop, identifying stocks that…
Coloplast A/S Friday, 6 February 2026 at 11:00-12:00am CET In connection with the publication of Coloplast’s interim financial results for Q1 2025/26, to be released same day around 07.30am CET, Coloplast will host a conference call to pre…
Investors with an interest in Medical - Instruments stocks have likely encountered both Coloplast A/S Sponsored ADR (CLPBY) and Penumbra (PEN). But which of these two stocks offers value investors a better bang for their buck right now? We…
Amidst a buoyant economic environment, the European markets have experienced notable gains, with the STOXX Europe 600 Index reaching new highs and major indices like Germany's DAX and France's CAC 40 posting significant increases. In this…
Coloplast A/S Today, Coloplast is announcing changes to the company’s Executive Leadership Team (ELT). The changes relate to the company’s Interventional Urology business as well as the global People & Culture function. Executive Vice Pres…
As European markets continue to show resilience, with major indices like the STOXX Europe 600 and Germany’s DAX posting notable gains, investors are keenly observing economic indicators such as inflation trends that suggest stability aroun…
Coloplast A/S Today, 4 December 2025, Coloplast A/S held its Annual General Meeting, at which the following resolutions were adopted: The annual report for the financial year 2024/25 was approved. Distribution of year-end dividend of DKK 1…
Company Logo The Diabetic Foot Ulcer Treatment Market offers growth opportunities due to rising diabetes prevalence, demand for cost-effective, painless treatments, and increased focus on advanced wound care and telemedicine. The expanding…
Coloplast A/S Notice of Annual General Meeting 2025 The Annual General Meeting of Coloplast A/S will be held on Thursday, 4 December 2025 at 3:30 pm CET at the premises of Coloplast A/S, Holtedam 3 in Humlebæk (the Aage Louis-Hansen Audito…
As the European markets navigate a period of mixed performance, with the pan-European STOXX Europe 600 Index recently dipping after reaching new highs, investors are closely monitoring central bank policies and inflation trends. In this en…
This article first appeared on GuruFocus. Release Date: November 04, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Coloplast AS (CLPBF) achieved 7% organic growth,…